Compound 15c, a Novel Dual Inhibitor of EGFR L858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers

In the past decades, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved as an effective treatment strategy for the patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, the tolerance for the EGFR-TKI always occurred after continuous administrati...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in pharmacology 2019, Vol.10, p.1533
Hauptverfasser:	Chen, Gaozhi, Bao, Yuyan, Weng, Qiaoyou, Zhao, Yingxin, Lu, Xiaoyao, Fu, Lili, Chen, Lingfeng, Liu, Zhiguo, Zhang, Xiaomin, Liang, Guang
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!